Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma-Reference-Cited by-同舟云学术

Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma

Published:2017-08-23 Issue:404 Volume:9 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Zhang Haipeng¹²^ORCID,Li Kai¹³,Lin Yuan¹⁴^ORCID,Xing Fan¹,Xiao Xiao¹⁵,Cai Jing¹,Zhu Wenbo¹,Liang Jiankai¹⁶,Tan Yaqian¹,Fu Liwu⁷,Wang Fang⁷,Yin Wei⁸,Lu Bingzheng¹,Qiu Pengxin¹,Su Xingwen¹,Gong Shoufang⁶,Bai Xuetao⁶,Hu Jun⁹,Yan Guangmei¹^ORCID

Affiliation:

1. Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China.

2. Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China.

3. Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disease, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou 510655, China.

4. Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China.

5. Department of Pharmacy, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.

6. Guangzhou Virotech Pharmaceutical Co. Ltd., Guangzhou 510663, China.

7. State Key Laboratory for Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

8. Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China.

9. Department of Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China.

Abstract

Inhibition of VCP sensitizes hepatocellular carcinoma cells to oncolytic virus M1–induced apoptosis.

Funder

National Natural Science Foundation of China

Guandong Natural Science Foundation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference57 articles.

1. Global cancer statistics, 2012

2. Hepatocellular Carcinoma

3. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation

4. Sorafenib in Advanced Hepatocellular Carcinoma

5. Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. VP5 protein of oncolytic herpes simplex virus type 2 induces apoptosis in A549 cells through TP53I3 protein;Virology;2024-07

2. Case Report and Literature Review of Multi-drugs Synergy and Targeted Comprehensive Treatment in Advanced Hepatocellular Carcinoma;Current Cancer Drug Targets;2024-03

3. CSN6‐SPOP‐HMGCS1 Axis Promotes Hepatocellular Carcinoma Progression via YAP1 Activation;Advanced Science;2024-02-02

4. Recent advances of engineered oncolytic viruses-based combination therapy for liver cancer;Journal of Translational Medicine;2024-01-02

5. SOCS3 inhibiting JAK-STAT pathway enhances oncolytic adenovirus efficacy by potentiating viral replication and T-cell activation;Cancer Gene Therapy;2023-12-15